Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ:ABOS
Want to see ABOS full AI Analyst Report?
Top Page
Acumen Pharmaceuticals
(NASDAQ:ABOS)
Select Model
Select Model
Rating:46Neutral
Price Target:
$2.50
▼(-11.35% Downside)
Action:Reiterated
Date:06/16/26
The score is primarily held down by weak financial performance (no revenue, sizable losses, and heavy cash burn implying ongoing funding risk). Technicals are neutral-to-soft with no clear momentum tailwind, and valuation is difficult to support with a negative P/E and no dividend. Offsetting these, management communicated generally positive clinical execution and upcoming milestones, with recent corporate updates supporting the pipeline narrative, but the late-2026 Phase II readout and limited runway keep risk elevated.
Positive Factors
Enhanced Brain Delivery (EBD) differentiation
Preclinical 14–40× higher brain exposure for EBD candidates indicates a structural pharmacologic advantage versus native antibodies. Improved brain penetration and distribution can materially increase target engagement, broaden treatable populations, and create durable differentiation versus competitors if safety translates in humans.
Negative Factors
High cash burn and runway risk
Sustained negative operating and free cash flow (~- $106M TTM) means the company must secure additional financing within months to sustain development. Recurrent capital raises dilute shareholders and create execution risk if market conditions or trial timelines shift, making financing a persistent structural vulnerability.
Read all positive and negative factors
Positive Factors
Negative Factors
Enhanced Brain Delivery (EBD) differentiation
Preclinical 14–40× higher brain exposure for EBD candidates indicates a structural pharmacologic advantage versus native antibodies. Improved brain penetration and distribution can materially increase target engagement, broaden treatable populations, and create durable differentiation versus competitors if safety translates in humans.
Read all positive factors
Acumen Pharmaceuticals (ABOS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$171.18M
Dividend YieldN/A
Average Volume (3M)315.15K
Price to Earnings (P/E)―
Beta (1Y)2.29
Revenue GrowthN/A
EPS Growth3.91%
CountryUS
Employees61
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.87
Shares Outstanding72,227,580
10 Day Avg. Volume329,277
30 Day Avg. Volume315,150
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.81
Price to Sales (P/S)0.00
P/FCF Ratio-1.11
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.60K
Enterprise Value/Ebitda-1.10
Forecast
1Y Price Target
$8.00Price Target Upside183.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.42
Revenue Forecast (FY)N/A
Acumen Pharmaceuticals Business Overview & Revenue Model
Company Description
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Acumen Pharmaceuticals does not have an established recurring product-revenue base from marketed drugs; commercial sales revenue is null. The company’s funding and cash inflows are primarily tied to f...
Acumen Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 12, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Positive
The call conveyed a generally positive tone driven by on-track clinical execution (ALTITUDE-AD), imminent milestones (ALTITUDE top-line readout late 2026; licensing decision for two EBD candidates in Q2 2026), encouraging preclinical EBD data (≈14–40x brain exposure), and controlled operating expenses. Key risks tempering the outlook include a cash runway only into early 2027 (necessitating future financing if programs extend), pending binary Phase II results that will determine the program's trajectory, competition and skepticism around the amyloid class, and the EBD program still being preclinical with an IND targeted for mid-2027.Positive Updates
ALTITUDE-AD Phase II On Track with Top-Line Readout Expected Late 2026
ALTITUDE-AD execution remains on track; participants transitioning into the 12-month open-label extension with a high conversion rate. The study is well-powered (≈542 subjects) to detect a statistically significant difference after 18 months on the primary endpoint (iADRS) and will report key secondary endpoints (CDR-SB), ARIA rates and biomarkers.
Negative Updates
Limited Cash Runway into Early 2027
Although the company holds $128.4 million, management expects these funds to support operations only into early 2027, which may require additional financing to fully support clinical and development plans if timelines extend or costs increase.
Read all updates
Q1-2026 Updates
Positive
Negative
ALTITUDE-AD Phase II On Track with Top-Line Readout Expected Late 2026
ALTITUDE-AD execution remains on track; participants transitioning into the 12-month open-label extension with a high conversion rate. The study is well-powered (≈542 subjects) to detect a statistically significant difference after 18 months on the primary endpoint (iADRS) and will report key secondary endpoints (CDR-SB), ARIA rates and biomarkers.
Read all positive updates
Company Guidance
The company reiterated near‑term clinical and development timing and quantitative plans: topline Phase II ALTITUDE‑AD results are expected in late 2026 (study powered to detect differences after 18 months on the iADRS primary endpoint, with key secondaries including CDR‑SB, ARIA and fluid/imaging biomarkers), the randomized 542‑subject study completed enrollment in March 2025 (in ~10 months) and participants are transitioning into a 12‑month open‑label extension with a high conversion rate; ALTITUDE is testing two active IV doses (35 mg/kg and 50 mg/kg) chosen to span the pharmacodynamic target‑engagement range seen in INTERCEPT‑AD. For the EBD program, Acumen expects to exercise its option to license two candidates in Q2 2026 and is targeting an IND in mid‑2027 (preclinical primate data show ~15–40× higher brain exposure and improved distribution versus unconjugated antibody), and JCR’s carrier has a clinically favorable anemia profile in Japan. Financially, Acumen reported $128.4M in cash and marketable securities as of March 31, 2026 (private placement grossed $35.75M in March), Q1 R&D of $16.5M, Q1 G&A of $4.7M, a loss from operations of $21.1M and a net loss of $20.7M, with cash runway expected into early 2027; operationally, use of plasma p‑tau217 in screening reduced negative PET rates from ~60% to under 20%.Acumen Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -46.00K | 0.00 | 0.00 | 0.00 | -169.00K | -12.30M |
| EBITDA | -108.82M | -116.93M | -98.08M | -51.61M | -42.69M | -100.60M |
| Net Income | -113.28M | -121.33M | -102.33M | -52.37M | -42.86M | -100.61M |
Balance Sheet | ||||||
| Total Assets | 133.63M | 122.83M | 238.99M | 310.13M | 196.59M | 230.33M |
| Cash, Cash Equivalents and Short-Term Investments | 128.40M | 116.86M | 171.56M | 243.52M | 177.60M | 194.24M |
| Total Debt | 31.16M | 31.31M | 29.70M | 28.49M | 105.00K | 0.00 |
| Total Liabilities | 46.15M | 52.40M | 57.18M | 43.15M | 7.81M | 5.15M |
| Stockholders Equity | 87.48M | 70.43M | 181.82M | 266.97M | 188.78M | 225.18M |
Cash Flow | ||||||
| Free Cash Flow | -105.55M | -115.63M | -86.23M | -43.09M | -35.31M | -18.00M |
| Operating Cash Flow | -105.55M | -115.54M | -86.22M | -43.06M | -35.15M | -17.96M |
| Investing Cash Flow | 91.44M | 133.93M | 48.03M | -171.67M | 39.19M | -104.12M |
| Financing Cash Flow | 35.74M | -34.00K | 6.93M | 151.75M | 3.91M | 200.47M |
Acumen Pharmaceuticals Technical Analysis
Neutral
2.82
Price Trends
2.48
Negative
2.61
Negative
2.22
Positive
Market Momentum
-0.05
Negative
47.52
Neutral
57.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABOS, the sentiment is Neutral. The current price of 2.82 is above the 20-day moving average (MA) of 2.35, above the 50-day MA of 2.48, and above the 200-day MA of 2.22, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 47.52 is Neutral, neither overbought nor oversold. The STOCH value of 57.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ABOS.
Acumen Pharmaceuticals Risk Analysis
Acumen Pharmaceuticals disclosed 85 risk factors in its most recent earnings report. Acumen Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acumen Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $220.49M | -3.22 | -41.31% | ― | ― | 73.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $171.18M | ― | -123.07% | ― | ― | 3.91% | |
46 Neutral | $22.83M | -0.36 | ― | ― | ― | ― | |
45 Neutral | $271.57M | -0.74 | 309.79% | ― | -35.61% | -68.92% | |
43 Neutral | $59.61M | -0.99 | -91.94% | ― | 106.65% | 12.20% |
* Healthcare Sector Average
ABOS
Acumen Pharmaceuticals
2.34
1.20
105.26%
VTGN
VistaGen Therapeutics
0.57
-1.79
-75.72%
IKT
Inhibikase Therapeutics
1.67
-0.27
-13.92%
SRZN
Surrozen
23.14
13.60
142.56%
TCRX
TScan Therapeutics
0.95
-0.58
-37.91%
Acumen Pharmaceuticals Corporate Events
Business Operations and StrategyProduct-Related Announcements
Acumen Advances Enhanced Brain Delivery Alzheimer’s Drug Candidates
Positive
Jun 16, 2026
On June 16, 2026, Acumen Pharmaceuticals announced it had nominated two Enhanced Brain Delivery development candidates, ACU301 and ACU401, for Alzheimer’s disease under its collaboration with JCR Pharmaceuticals and exercised its option to l...
Executive/Board ChangesShareholder Meetings
Acumen Stockholders Approve Directors and Equity Incentive Plan
Positive
Jun 3, 2026
On June 3, 2026, Acumen Pharmaceuticals, Inc. held its 2026 annual meeting of stockholders, with about 79% of the 72.2 million outstanding shares present or represented by proxy. Stockholders elected three Class II directors, George Golumbeski, Ph...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Acumen Updates Q1 Results and Alzheimer’s Pipeline Progress
Positive
May 12, 2026
On May 12, 2026, Acumen Pharmaceuticals reported first quarter 2026 results and updated investors on progress in its Alzheimer’s pipeline, highlighting continued execution of the ALTITUDE-AD Phase 2 trial of sabirnetug, which completed enrol...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Acumen Updates Alzheimer’s Pipeline, Extends Cash Runway Into 2027
Positive
Mar 26, 2026
On March 26, 2026, Acumen Pharmaceuticals reported full-year 2025 results and updated investors on progress in its Alzheimer’s pipeline, highlighting ongoing Phase 2 development of sabirnetug and expansion of its Enhanced Brain Delivery plat...
Business Operations and StrategyPrivate Placements and Financing
Acumen Raises Capital to Advance Enhanced Brain Delivery
Positive
Mar 16, 2026
On March 13, 2026, Acumen Pharmaceuticals agreed to sell 10,833,331 common shares at $3.30 each in a private placement to institutional accredited investors, raising expected gross proceeds of about $35.75 million to support its Enhanced Brain Del...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.